Infect Chemother.  2013 Sep;45(3):272-282. 10.3947/ic.2013.45.3.272.

Vaccination of Hematopoietic Stem Cell Transplantation Recipients: Perspective in Korea

• Lee DG

• KMID: 2170426
• DOI: http://doi.org/10.3947/ic.2013.45.3.272

Abstract

Antibody titers to vaccine-preventable diseases such as tetanus, polio, measles, mumps, and rubella decline within 1-10 years after allogeneic or autologous hematopoietic stem cell transplantation (SCT) if the recipient is not vaccinated. Vaccine-preventable diseases such as pneumococcal diseases, Haemophilus influenzae type b infections, influenza, measles, and varicella can pose an increased risk for SCT recipients. Therefore, after SCT, the recipients should be routinely revaccinated. Vaccination recommendations have previously been developed and published by the European Group of Blood and Marrow Transplantation and the Centers for Disease Control, by the Infectious Diseases Society of America, and by the American Society for Blood and Marrow Transplantation in 2009. Different epidemiologies and strategies have existed in Korea. In 2012, the Korean Society of Infectious Diseases published "Vaccination for Adult" describing the guidelines for vaccination, one of the chapters assigned for vaccination of SCT recipients. The present article reviews the current available vaccination strategies for SCT recipients, their family members, and healthcare workers, with the focus on recent Korean perspectives.

Keyword

Stem cell transplantation; Vaccination; Graft versus host disease; Immune response; Infection

MeSH Terms

Americas
Bone Marrow
Centers for Disease Control and Prevention (U.S.)
Chickenpox
Communicable Diseases
Delivery of Health Care
Graft vs Host Disease
Haemophilus influenzae type b
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
Humans
Influenza, Human
Korea
Measles
Mumps
Poliomyelitis
Rubella
Stem Cell Transplantation
Tetanus
Transplants
Vaccination

Reference

1. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am. 2010; 24:257–272.

2. Rezvani AR, Deeg HJ. Introduction to hematopoietic cell transplantation. In : Bowden RA, Ljungman P, Snydman DR, editors. Transplant infections. 3rd ed. Philadelphia: Lippincott Williams & Wilkins;2010. p. 1–12.

3. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007; 357:1472–1475.

4. Lee JW, Kim CC. The activity of hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant. 2008; 42:Suppl 1. S92–S95.

5. Lee DG. Common infectious diseases in hematopoietic stem cell transplant recipients. Korean J Med. 2013; 84:158–167.

6. Dropulic LK, Lederman HM. Overview of infections in the immunocompromised host. In : Hayden RT, Carroll KC, Tang YW, Wolk DM, editors. Diagnostic microbiology of the immunocompromised host. 1st ed. Washinton, DC: ASM Press;2009. p. 3–43.

7. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011; 53:798–806.

8. Socié G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, Korthof E, Weis J, Levy V, Tichelli A. Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003; 101:3373–3385.

9. Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, Wagner JL, Witherspoon RP, Anasetti C, Appelbaum FR, Bensinger WI, Deeg HJ, Martin PJ, Sanders JE, Storb R, Storek J, Wade J, Siadak M, Flowers ME, Sullivan KM. Incidence, risk factors and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003; 32:515–522.

10. Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J, Ljungman P. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007; 40:1055–1062.

11. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010; 115:3861–3868.

12. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ. Center for International Blood and Marrow Research. National Marrow Donor program. European Blood and MarrowTransplant Group. American Society of Blood and Marrow Transplantation. Canadian Blood and Marrow Transplant Group. Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Association of Medical Microbiology and Infectious Disease Canada. Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15:1143–1238.

13. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, Small T. Center for International Blood and Marrow Transplant Research. National Marrow Donor Program. European Blood and Marrow Transplant Group. American Society of Blood and Marrow Transplantation. Canadian Blood and Marrow Transplant Group. Infectious Disease Society of America. Society for Healthcare Epidemiology of America. Association of Medical Microbiology and Infectious Diseases Canada. Centers for Disease Control and Prevention. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009; 44:521–526.

14. Hilgendorf I, Freund M, Jilg W, Einsele H, Gea-Banacloche J, Greinix H, Halter J, Lawitschka A, Wolff D, Meisel R. Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. Vaccine. 2011; 29:2825–2833.

15. Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, Rubin RH, Sepkowitz KA. Centers for Disease Control and Prevention. Infectious Diseases Society of America. American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2001; 392–421.

16. Ljungman P, Engelhard D, de la Cámara R, Einsele H, Locasciulli A, Martino R, Ribaud P, Ward K, Cordonnier C. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2005; 35:737–746.

17. Styczynski J, Gil L. Paediatric Diseases Working Party. Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplant. 2008; 42:Suppl 2. S77–S81.

18. Ljungman P, Small TN. vaccination recommendations writing group. Update to vaccination guidelines. Biol Blood Marrow Transplant. 2010; 16:1608–1609.

19. Lee DG, Yoo JH. Hematopoietic stem cell transplantation. In : Cheong HJ, editor. Vaccination for adult. 2nd ed. Seoul: MIP Press;2012. p. 380–388.

20. Small TN, Cowan MJ. Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases. Expert Rev Clin Immunol. 2011; 7:193–203.

21. Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R, Dekker AW, Prentice HG, Gustavsson A, Nurnberger W, Ljungman P. Infectious Disease Working Party of the European Bone Marrow Transplantation (IDWP-EBMT). Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002; 117:444–450.

22. Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infection in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore). 2007; 86:69–77.

23. Debbache K, Varon E, Hicheri Y, Legrand P, Donay JL, Ribaud P, Cordonnier C. The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines? Clin Microbiol Infect. 2009; 15:865–868.

24. Kumar D, Chen MH, Welsh B, Siegal D, Cobos I, Messner HA, Lipton J, Humar A. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis. 2007; 45:1576–1582.

25. Kumar D, Humar A, Plevneshi A, Siegal D, Franke N, Green K, McGeer A. Toronto Invasive Bacterial Diseases Network. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant. 2008; 41:743–747.

26. Cheong HJ. Vaccination necessary for Korean adults. J Korean Med Assoc. 2011; 54:1289–1296.

27. Cordonnier C, Labopin M, Chesnel V, Ribaud P, De La Camara R, Martino R, Ullmann AJ, Parkkali T, Locasciulli A, Yakouben K, Pauksens K, Einsele H, Niederwieser D, Apperley J, Ljungman P. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009; 48:1392–1401.

28. Cordonnier C, Labopin M, Chesnel V, Ribaud P, Camara Rde L, Martino R, Ullmann AJ, Parkkali T, Locasciulli A, Yakouben K, Pauksens K, Bonnet E, Einsele H, Niederwieser D, Apperley J, Ljungman P. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010; 28:2730–2734.

29. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004; 39:1300–1306.

30. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D. Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation. Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011; 96:1231–1235.

31. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis. 2013; 15:219–232.

32. Ditschkowski M, Elmaagacli AH, Beelen DW. H1N1 in allogeneic stem cell recipients: courses of infection and influence of vaccination on graft-versus-host disease (GVHD). Ann Hematol. 2011; 90:117–118.

33. Choi SM, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood. 2011; 117:5050–5056.

34. Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, Lee YJ, Lee HB, Lim CM, Koh Y. Korean Society of Critical Care Medicine H1N1 Collaborative. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 2011; 183:1207–1214.

35. Espinosa-Aguilar L, Green JS, Forrest GN, Ball ED, Mariaz RT, Strasfeld L, Taplitz RA. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences. Biol Blood Marrow Transplant. 2011; 17:566–573.

36. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefits of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005; 36:897–900.

37. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant. 2008; 42:637–641.

38. Li Volti S, Mauro L, Di Gregorio F, Romeo MA, Lupo L, Pizzarelli G, Mangiagli A, Giammanco G, Russo G. Immune status and immune response todiphtheria-tetanus and polio vaccines in allogeneic bone marrow-transplanted thalassemic patients. Bone Marrow Transplant. 1994; 14:225–227.

39. Hewlett EL, Edwards KM. Pertussis-not just for kids. N Engl J Med. 2005; 352:1215–1222.

40. Choi JH, Choo EJ, Huh A, Choi SM, Eom JS, Lee JS, Park SH, Kang JH. Immunogenicity and safety of diphtheria-tetanus vaccine in adult. J Korean Med Sci. 2010; 25:1727–1732.

41. Škovránková J, Petráš M. Persistence of humoral immunity to tetanus and diphtheria in hematopoietic stem cell transplant recipients after post-transplant immunization. Pediatr Blood Cancer. 2012; 59:908–913.

42. Parkkali T, Käyhty H, Hovi T, Olander RM, Roivainen M, Volin L, Ruutu T, Lahdenkari M, Ruutu P. A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2007; 39:179–188.

43. Storek J, Dawson MA, Lim LC, Burman BE, Stevens-Ayers T, Viganego F, Herremans MM, Flowers ME, Witherspoon RP, Maloney DG, Boeckh M. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant. 2004; 33:337–346.

44. Idilman R, Ustün C, Karayalçin S, Aktemel A, Turkyilmaz AR, Ozcan M, Arslan O, Bozdayi AM, Van Thiel DH, Akan H. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clin Transplant. 2003; 17:438–443.

45. Idilman R, Arat M. Evaluation and management of hepatitis B virus infectionin hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther. 2011; 9:641–652.

46. Jaffe D, Papadopoulos EB, Young JW, Orelly RJ, Prockop S, Kerman NA, Jakubowski A, Boulad F, Perales MA, Castro-Malaspina H, Small TN. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood. 2006; 108:2470–2475.

47. Na BK, Shin JM, Lee JY, Shin GC, Kim YY, Lee JS, Lee JK, Cho HW, Lee HJ, Rota PA, Bellini WJ, Kim WJ, Kang C. Genetic and antigenic characterization of measles viruses that circulated in Korea during the 2000-2001 epidemic. J Med Virol. 2003; 70:649–654.

48. Lee DG, Yoo JH, Choi JH, Choi SM, Park SH, Kim YJ, Kim DW, Shin WS, Kim CC. A fatal case of measles pneumonia complicating an adult recipient of hemopoietic stem cell transplantation during the nationwide epidemic in Korea. Int J Infect Dis. 2006; 10:410–411.

49. Yoo JH, Lee DG, Choi SM, Choi JH, Park YH, Kim YJ, Kim HJ, Lee S, Kim DW, Lee JW, Min WS, Shin WS, Kim CC. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant. 2004; 34:497–504.

50. Lee DG, Park ST, Na BK, Choi JH, Shin WS, Paik SY, Shin JM, Kang C, Kim WJ, Lee HJ, Kim CC. Characteristics of respiratory tract infections in the hematopoietic stem cell transplantation population. Korean J Infect Dis. 2001; 33:419–429.

51. Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G, Linde A, Ringdén O, Wahren B. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989; 159:610–615.

52. Ljungman P, Aschan J, Barkholt L, Broliden PA, Gustafsson B, Lewensohn-Fuchs I, Löfgren C, Winiarski J, Ringdén O. Measles immunity after allogeneic stem cell transplantation influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant. 2004; 34:589–593.

53. Lee SH, Choi SM, Park YH, Park SG, Kim YJ, Chung MS, Choi JH, Yoo JH, Shin WS, Min WS, Kim CC, Kim DJ. Changes in antibody titers of measles, mumps, rubella, and hepatitis B virus after bone marrow transplantation in Korea: a preliminary report. Korean J Infect Dis. 1998; 30:558–563.

54. Machado CM, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005; 35:787–791.

55. Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, Kaneda M, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Masauji N, Matsunaga T, Mori A, Mukai M, Nishio M, Noto S, Ota S, Sakai H, Suzuki N, Takahashi T, Tanaka J, Torimoto Y, Yoshida M, Fukuhara T. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol Blood Marrow Transplant. 2009; 15:724–729.

56. Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, Knowles MA, Papadopoulos EB, Casson A, Copeland C, Torok-Castanza J, Zakak N, Ruggiero J, Small TN. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011; 17:1708–1713.

57. Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant. 2010; 45:1602–1606.

58. Tedeschi SK, Savani BN, Jagasia M, Engelhardt B, Anasetti C, Barrett AJ, Lee S. Time to consider HPV vaccination after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 16:1033–1036.

59. Carreras E. Risk assessment in haematopoietic stem cell transplantation: the liver as a risk factor. Best Pract Res Clin Haematol. 2007; 20:231–246.